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Objective(s):Neuropathic pain due to lesion or dysfunction of the peripheral or central nervous system is often
refractory to the conventional analgesics. Currently, there is no proven treatment to prevent or cure
neuropathic pain. A recent surge of new data suggests the potential effects of vitamin D in the medical
community. This study was designed to determine whether acute or chronic vitamin D administration was
effective in alleviating symptoms of neuropathic pain in a rat model of neuropathic pain.
Materials and Methods: Neuropathic pain was induced by chronic constriction injury (CCI) of the sciatic
nerve in the rats that resulted in thermal hyperalgesia, mechanical, and cold allodynia.
Results: Acute vitamin D injections (250, 500, and 1000 unit/kg i.p.) on the 7th, 14th, and 21st postoperative
days could not attenuate mechanical and cold allodynia as well as heat hyperalgesia compared to CCI
group. But when vitamin D (1000 unit/kg i.p.) administration was started on the first day after surgery and
given daily until the 21st day, cold allodynia and heat hyperalgesia considerably were attenuated.
However, no differences in paw withdrawal thresholds were observed.
Conclusion: These results indicate that chronic vitamin D administrations can attenuate the behavioral scores
of neuropathic pain in rats.
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Introduction
Neuropathic pain which is caused by primary or sec-
ondary damage of the nervous system characterizes
by hyperalgesia, allodynia, and spontaneous pain.1
There are multiple anatomical sites of lesions in the
neuropathic pain.2 In these patients, pain is usually
chronic, spontaneous, and/or stimuli-evoked and
sometimes difficult to treat.3 Despite intensive
research on the neurobiological mechanisms involved
in this chronic pain, effective therapy and the under-
lying mechanisms are poorly detect.4,5 The opioids
in this pain state have limited efficacy as compared
to other pain states.6 Therefore, the development of
more efficacious analgesics with improved side effect
profiles is currently a major focus.7
Vitamin D is a fat-soluble secosteroid.8 The emer-
gence of new data suggests that the benefits of
Vitamin D extend beyond healthy bones.9 Recently,
the relationship between pain and Vitamin D is inves-
tigated.10 There are various forms of Vitamin D; the
most common forms are VitaminD3 (cholecalciferol)
and Vitamin D2 (ergocalciferol).11 Vitamin D
deficiency linked to a headache, abdominal, knee
and back pain, and also with fibromyalgia.12 Long-
term Vitamin D deficiency weakens the immune
system and leads to chronic inflammation.13
Experimental studies showed that inflammation leads
to the hyperalgesia.14 Patients suffering from neuro-
pathic pain usually experience other comorbidities
such as sleep, anxiety, and mood disorders.15 An ade-
quate level of Vitamin D improves the quality of life.16
Research in the area of chronic pain and Vitamin D
deficiency remains limited. Thus, more research is
necessary to determine whether Vitamin D is useful
in the treatment of various types of pain. So this
study was designed to determine whether acute or
chronic Vitamin D administration was effective in
attenuating hypersensitivity in a rat model of neuro-
pathic pain.
Material and methods
Animals and housing conditions
The experiments were performed on male Sprague–
Dawley rats (200–250 g). They were housed four per
cage, in a room under controlled temperature (23±
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2°C), humidity (50%), and lighting (12/12 h light/
dark cycle), with food and water available ad libitum.
All experiments were approved by the ethical commit-
tee of Shiraz University of Medical sciences inter-
national branches and followed the European
Commission Directive (86/609/EEC) for animal
experiments.
Chemicals
Vitamin D was obtained from Darupakhsh pharma-
ceutical Co., Iran. Acetone was bought from Iran
Kave Co., Iran. Vitamin D was diluted in almond oil.
Neuropathic pain model
The rats were anesthetized with ketamine (50 mg/kg
i.p.) and xylazine (10 mg/kg i.p.). The common
sciatic nerve was exposed and dissected from sur-
rounding connective tissue. Four ligatures (4.0
chromic Gut) were tied loosely around the common
sciatic nerve with a 1–1.5 mm interval between liga-
tures. Sham-operated rats had the same surgery, the
left common sciatic nerve was exposed but no ligation
was made.17 The rats were housed individually in
cages after the surgery. All experiments followed the
guide lines on the ethical standard for investigation
of experimental pain in animals and were also
approved by the Research.
Behavioral tests of neuropathic pain
Heat hyperalgesia, cold, and mechanical allodynia
were determined by using the radiant heat plantar,
acetone, and von Frey test, respectively, as the behav-
ioral score of neuropathic pain. After cage exploration
and major grooming activities ceased, the behavioral
tests were done. The hypersensitivity to the neuro-
pathic pain was determined 1 day before the surgery
as the baseline value and also 45 min after the injec-
tions on the 7th, 10th, 14th, and 21st postoperative
days.18
Thermal hyperalgesia (plantar test)
Paw withdrawal latency in response to radiant heat was
measured by using plantar test apparatus (Ugo Basile,
Varese, Italy). Thermal withdrawal latency was
defined as the latency (seconds) between the heat stimu-
lus onset and paw withdrawal using a feedback-con-
trolled shut-down unit. A cut-off time of 22 s was
used to avoid tissue damage. Mean latency of the with-
drawal response for ipsilateral (operated) and contralat-
eral (non-operated) paws was calculated separately.19
Cold allodynia (acetone test)
Cold allodynia was performed with using the acetone
spray test (evaporation-evoked cooling) as described
previously. The frequency of paw withdrawal was
expressed as a percentage (the number of paw withdra-
wals/number of trials × 100).20
Mechanical allodynia (von Frey filament
stimulation)
To examine mechanical allodynia, withdrawal
threshold to mechanical stimuli was measured using
von Frey filaments (steeling, Wood Dale, IL, USA)
in the following order: 0.6, 1.0, 1.4, 2.0, 4.0, 6.0, 8.0,
10.0, 15.0, 26.0 and 60 g.21
Treatment
Because common clinical practice indicates that neuro-
protective interventions should be used immediately
after the injury, it was further hypothesized that
early vitamin D treatment would be more effective
than treatment initiated after pain hypersensitivity
has been established. To compare early versus late
treatment, rats were given vitamin D, starting immedi-
ately after surgery and continued daily until the 21st
day. The effects of acute injection of vitamin D on
pain hypersensitivity were also tested at 45 min after
administration, on the 7th, 14th, and 21st days after
surgery.
Intermittent treatment
Rats were injected intraperitoneally with the vehicle
and the baseline paw withdrawal thresholds were
measured. Vitamin D (250, 500, and 1000 unit/kg
i.p.) had been injected on the 7th, 14th, and 21st
days after surgery, at 45 min before the behavioral
tests.
Repeated treatment
Drug or vehicle was administered during the onset
phase of model development. These times were
chosen to clarify the possible effects of repeated
vitamin D administration during the onset phase of
the model. Vitamin D (250, 500, and 1000 unit/kg
i.p.) was administered one day after surgery and con-
tinued once daily for 20 additional days. Behavioral
tests were done on the 7th, 14th, and 21st days after
surgery.22
The vehicle groups were given almond oil injections
according to the same schedule.
For repeated treatment, injections were always given
45 min before measurement of paw withdrawal
thresholds, withdrawal frequency, and paw withdrawal
latency.23
Statistical analysis
Parametric data were analyzed by one-way analysis of
variance (ANOVA) followed by Tukey post-hoc test
for multiple comparisons. Time-course analysis of
the behavioral data was compared by ANOVA
repeated measures for heat hyperalgesia and cold allo-
dynia tests.24 Moreover, the nonparametric data
resulted from von Frey test were converted to para-
metric data by rank transformation method and new
data were analyzed by ANOVA.25
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Results
Behavioral responses of chronic constriction
injury model of neuropathic pain
Sciatica nerve ligation did not damage the motor
activity and the rats seemed healthy. The appearance
of the surgical paw slightly changed but this did not
interfere with the normal activity of the rats.
The sciatic nerve ligation decreased paw withdrawal
latency to the thermal stimulus significantly (P< 0.001),
but the control group did not produce any significant
change in the withdrawal latency (Fig. 1A).
Application of acetone to the medial surface of the
nerve-ligated hind paw led to the significant rises in
the withdrawal frequency of the chronic constriction
injury (CCI) group compared to the control group
Fig. 1B (P< 0.001). Also, Fig. 1C shows the results
of the behavioral tests for the mechanical allodynia.
Sciatic nerve ligation significantly enhanced the sensi-
tivity of the ipsilateral hind paw to the mechanical
(a)
(b)
(c)
Figure 1 Behavioral responses of CCI model of the
neuropathic pain. (A) The effects of CCI of the sciatic nerve on
the heat hyperalgesia. (B) The effects of CCI of the sciatic
nerve on the cold allodynia. (C) The effects of CCI of sciatic
nerve on mechanical allodynia. The results are expressed as
mean± S.E.M., n= 8 in all groups. ###P< 0.001 versus CCI
group. Results from von Frey test (Fig. 1C) are expressed as
mean rank± S.E.M. The vehicle groups (CCI) received almond
oil according to the treatment schedule. Control group had
the same surgery, the left common sciatic nervewas exposed
but no ligation was made.
(a)
(b)
(c)
Figure 2 The effects of vitamin D on the expression of
neuropathic pain. (A) The effect of acute treatment with
vitamin D (250, 500, and 1000 unit/kg i.p.) on the expression of
heat hyperalgesia. (B) The effect of acute treatment with
vitamin D (250, 500, and 1000 unit/kg i.p.) on the expression of
cold allodynia. (C) The effect of acute treatment with vitamin
D (250, 500, and 1000 unit/kg i.p.) on the expression of
mechanical allodynia. The results are expressed as mean±
S.E.M., n= 8 in all groups. Results from von Frey test (Fig. 2C)
are expressed as mean rank± S.E.M. The vehicle groups
(CCI) received almond oil according to the treatment
schedule.
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stimuli. There is a significant enhanced response to the
mechanical stimulus in the CCI group compared to the
control group (P< 0.001). Contralateral hyperalgesia
and allodynia did not occur throughout the exper-
iment in all groups.
The effects of vitamin D on the expression of
neuropathic pain
Acute administration of vitamin D (250, 500, and
1000 units/kg i.p.) on the 7th, 14th, and 21st days
after surgery, 30 min before the behavioral tests did
not produce any significant changes in the heat hyper-
algesia, cold, and mechanical allodynia in the nerve-
ligated rats when compared to the vehicle group
(Fig. 2A, B, and C). These results indicate that single
administration of vitamin D did not affect the
expression of neuropathic pain.
The effects of vitamin D on the development of
neuropathic pain
To study the effects of vitaminDon the development of
neuropathic pain, it was administered repeatedly from
the first day after surgery until the 21st post-surgery
day. Fig. 3A shows the effects of vitamin D on the
development of thermal hyperalgesia. Repeated
administration of vitamin D (1000 unit/kg i.p., P<
0.01) increased the paw withdrawal latency on the
14th and (500 and 1000 unit/kg i.p., P< 0.001) on
the 21st post-surgery days. Moreover, chronic adminis-
tration of vitamin D (250, 500 and 1000 unit/kg i.p.)
significantly attenuates cold allodynia (Fig. 3B) (P<
0.001). Finally, chronic administration of vitamin D
could not significantly modify withdrawal threshold
of the nerve-ligated paw (Fig. 3C).
Discussion
Considering our results acute treatment with vitamin
D on the 7th, 14th, and 21st days after surgery did
not alter pain hypersensitivity compared to the
vehicle-treated rats. Although when vitamin D admin-
istration was started on the first day after surgery and
given daily until the 21st day, cold allodynia and heat
hyperalgesia significantly decreased. However, chronic
administration of vitamin D could not affect hypersen-
sitivity to the mechanical stimulus in nerve-ligated
paw. This difference is probably due to different
nociceptors and neuronal pathways involved in differ-
ent sensory modalities. Vitamin D receptors (VDRs)
are widely distributed in the central nervous
system.26,27 Analysis of rat’s dorsal root ganglia
(DRG) revealed the presence of VDRs and its metabo-
lizing enzymes in the nociceptive neurons of DRG.28
Vitamin D insufficiency impacts sensory processes
such as pain and nociception. Moreover, inflamma-
tory events disturb the VDR signaling in the central
nervous system.29 Also, a significant increase in
VDR expression was observed in DRG neurons fol-
lowing neuropathic pain. Furthermore, the greatest
increase in VDR expression was observed in small
diameter neurons.30 Consequently, vitamin D may
affect sensory neurons especially, small diameter
neurons. Considering our results, acute or chronic
vitamin D administration did not affect mechanical
allodynia. Non-noxious mechanical stimulus is trans-
mitted primarily through the low threshold, large
diameter, myelinated Aβ fibers, while the cold stimulus
(a)
(b)
(c)
Figure 3 The effects of vitamin D on the development of
neuropathic pain. (A) The effect of chronic treatment with
vitamin D (250, 500 and 1000 unit/kg i.p.) from 1st day to the
21st day after surgery on the development of heat
hyperalgesia. (B) The effect of chronic treatment with vitamin
D (250, 500, and 1000 unit/kg i.p.) from 1st day to the 21st day
after surgery on the development of cold allodynia. (C) The
effect of chronic treatment with vitamin D (250, 500, and 1000
unit/kg i.p.) from 1st day to the 21st day after surgery on the
development of mechanical allodynia. The results are
expressed as mean± S.E.M., n= 8 in all groups.**P< 0.01,
***P< 0.001 versus vehicle group. Results from von Frey test
(Fig. 3C) are expressed as mean rank± S.E.M. The vehicle
groups (CCI) received almond oil according to the treatment
schedule.
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is chiefly transmitted to the spinal cord through the
high threshold, thin unmyelinated primary C-fiber
nociceptors.31 Probably due to the greatest expression
of VDRs in small diameter neurons following neuro-
pathic pain, vitamin D was ineffective on mechanical
allodynia. Thus, these results indicate that vitamin
D, when administered immediately after nerve injury,
and for a sufficient period of time, can prevent the
development of cold allodynia and heat hyperalgesia
in rats. This is in accordance with results obtained by
Lee et al. Their results showed that vitamin D
repletion in diabetic subjects with painful diabetic neu-
ropathy decreases pain scores.32
Several experimental models of peripheral neuropa-
thy in rats were developed. In this study, we used CCI
of the sciatic nerve as an animal model of neuropathic
pain.33–35 Nerve ligation resulted in high degree of
hypersensitivity against the thermal and mechanical
stimulus. As described, each treatment protocol
affected these parameters to varying degrees. So differ-
ent mechanisms might be involved in the antinocicep-
tive effects of vitamin D. Vitamin D inhibits the
synthesis of nitric oxide synthase (iNOS) in microglia
and astrocytes.36 The increased production of NO is
important to maintenance the pain hypersensitivity
and contributes to the development of central sensitiz-
ation and involved in the nociceptive process.37
Inhibition of iNOS by Vitamin D is a potential mech-
anism for reducing pain and neuronal damage after
injury.38 Vitamin D can modulate neuronal excit-
ability likes other neuroactive steroids.39 Neuroactive
steroids control the plasticity of the nervous system.
This includes spontaneous regular firing, intrinsic
excitability, action potential duration, and sensitivity
to neurotransmitters.40–42 Vitamin D as a neuroactive
steroid triggers a variety of signal transduction
systems. Vitamin Dmodulates brain neurotransmitters
and also upregulates the synthesis of neural growth
factor (NGF).43 In the diabetic neuropathic pain
model, vitamin D increased NGF production and
prevent neurotrophic deficits.44 There is some evidence
that vitamin D produces a neuroprotective effect by
decreasing the effects of glucocorticoids and by mod-
ulating neuronal calcium ion homeostasis.45
Vitamin D inhibits COX-2 expression and
influences prostaglandins by stimulating 15-prosta-
glandin dehydrogenase (15-PGDH) expression. The
enzyme 15-PGDH degrades prostaglandins and inhi-
bits prostaglandin-E2 receptor (PGE2) subtypes.46
Prostaglandins reduce the firing threshold and
mediate neuropathic pain in the spinal cord.47
Vitamin D affects inflammatory pathways associated
with chronic pain.48,49 Vitamin D suppresses TNF-?
and macrophage colony-stimulating factor in astro-
cytes and microglia. TNF-? strongly associated with
both peripheral and central sensitization.50
Conclusion
These results indicate that vitamin D supplementation
can attenuate the hypersensitivity of the neuropathic
pain in rats. These results bring up the beneficial
effects of vitamin D in the management of neuropathic
pain. However, further pre-clinical and clinical studies
are needed to validate this effect and establish the
effective doses of vitamin D in human, when prescrib-
ing for pain.
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